nach oben

Erschienen in:

03.01.2019 | Original Research Article

Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery

verfasst von: Tomoyuki Mizuno, Katja M. Gist, Zhiqian Gao, Michael F. Wempe, Jeffrey Alten, David S. Cooper, Stuart L. Goldstein, Alexander A. Vinks

Erschienen in: Clinical Pharmacokinetics | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Milrinone is used for the prevention of low cardiac output syndrome in pediatric patients after cardiac surgery. Milrinone is mainly eliminated by the kidneys; however, there is limited information on milrinone pharmacokinetics in infants who have acute kidney injury (AKI). The aim of this study was to develop a milrinone population pharmacokinetic model in neonates and infants with or without AKI. The developed milrinone pharmacokinetic model was utilized for a Monte Carlo simulation analysis to identify age-appropriate dosing regimens in neonates and infants.

Methods

Population pharmacokinetic analysis was performed with a total of 1088 serum milrinone concentrations obtained from 92 infants as part of a prospective clinical study in neonates and infants following cardiac surgery (ClinicalTrials.gov identifier NCT01966237). AKI stages were determined based on the Kidney Injury Improving Global Outcomes (KDIGO) Clinical Practice Guideline within the first three postoperative days.

Results

A two-compartment model was found to adequately describe the pharmacokinetic data. Allometrically scaled body weight, AKI stages, and maturation function were identified as significant predictors of milrinone clearance. The proposed dosing regimens for milrinone continuous infusions were determined based on a target concentration attainment of simulated steady-state concentration and covered three age groups across 0–12 months of age for each AKI stage.

Conclusion

This study provides a milrinone population pharmacokinetic model in neonates and infants and captures the developmental changes in clearance. Age-appropriate dosing regimens were determined based on the simulation analysis with the developed pharmacokinetic model. The findings will facilitate model-informed precision dosing of milrinone in infants with or without AKI.

Nur mit Berechtigung zugänglich

Lomivorotov VV, Efremov SM, Kirov MY, Fominskiy EV, Karaskov AM. Low-cardiac-output syndrome after cardiac surgery. J Cardiothorac Vasc Anesth. 2017;31(1):291–308.CrossRefPubMed

Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107(7):996–1002.CrossRefPubMed

Gist KM, Goldstein SL, Joy MS, Vinks AA. Milrinone dosing issues in critically ill children with kidney injury: a review. J Cardiovasc Pharmacol. 2016;67(2):175–81.CrossRefPubMed

Gist KM, Mizuno T, Goldstein SL, Vinks A. Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury. Ther Drug Monit. 2015;37(6):792–6.CrossRefPubMed

Taniguchi T, Shibata K, Saito S, Matsumoto H, Okeie K. Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. Intensive Care Med. 2000;26(8):1089–93.CrossRefPubMed

Larsson R, Liedholm H, Andersson KE, Keane MA, Henry G. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol. 1986;29(5):549–53.CrossRefPubMed

Cox ZL, Calcutt MW, Morrison TB, Akers WS, Davis MB, Lenihan DJ. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. J Cardiovasc Pharmacol Ther. 2013;18(5):433–8.CrossRefPubMed

Bishara T, Seto WT, Trope A, Parshuram CS. Use of milrinone in critically ill children. Can J Hosp Pharm. 2010;63(6):420–8.PubMedPubMedCentral

Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC Jr. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology. 1994;81(3):616–22.CrossRefPubMed

10.

Paradisis M, Jiang X, McLachlan AJ, Evans N, Kluckow M, Osborn D. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2007;92(3):F204–9.CrossRefPubMed

11.

Zuppa AF, Nicolson SC, Adamson PC, Wernovsky G, Mondick JT, Burnham N, et al. Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. Anesth Analg. 2006;102(4):1062–9.CrossRefPubMed

12.

Bailey JM, Miller BE, Lu W, Tosone SR, Kanter KR, Tam VK. The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. Anesthesiology. 1999;90(4):1012–8.CrossRefPubMed

13.

Butterworth JFt, Hines RL, Royster RL, James RL. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg. 1995;81(4):783–92.PubMed

14.

Ramamoorthy C, Anderson GD, Williams GD, Lynn AM. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg. 1998;86(2):283–9.PubMed

15.

Bailey JM, Hoffman TM, Wessel DL, Nelson DP, Atz AM, Chang AC, et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. J Pharmacokinet Pharmacodyn. 2004;31(1):43–59.CrossRefPubMed

16.

Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.CrossRefPubMed

17.

Gist KM, Cooper DS, Wrona J, Faubel S, Altmann C, Gao Z, et al. Acute kidney injury biomarkers predict an increase in serum milrinone concentration earlier than serum creatinine-defined acute kidney injury in infants after cardiac surgery. Ther Drug Monit. 2018;40(2):186–94.CrossRefPubMedPubMedCentral

18.

Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241–57.CrossRefPubMed

19.

Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.CrossRefPubMed

20.

Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.CrossRefPubMed

21.

Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486–95.CrossRefPubMed

22.

Holford N. The visual predictive check - superiority to standard diagnostic (Rorschach) plots [abstract no. 738]. Annual meeting of the population approach group in Europe (PAGE); 16–17 Jun 2005; Pamplona.

23.

National Health and Nutrition Examination Survey. Questionnaires, datasets, and related documentation. https://wwwn.cdc.gov/nchs/nhanes/Default.aspx. Accessed 10 Dec 2018.

24.

Mouksassi MS, Marier JF, Cyran J, Vinks AA. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther. 2009;86(6):667–71.CrossRefPubMed

25.

Mizuno T, Fukuda T, Emoto C, Mobberley-Schuman PS, Hammill AM, Adams DM, et al. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer. 2017;64(8):e26470.CrossRef

26.

Kikura M, Levy JH, Michelsen LG, Shanewise JS, Bailey JM, Sadel SM, et al. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. Anesth Analg. 1997;85(1):16–22.PubMed

27.

Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 2014;53(4):327–46.CrossRefPubMed

28.

Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther. 2015;98(3):298–308.CrossRefPubMed

29.

Anderson BJ, Holford NH. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child. 2013;98(9):737–44.CrossRefPubMed

30.

Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67–76.CrossRefPubMed

31.

Anderson BJ, Holford NH. Tips and traps analyzing pediatric PK data. Paediatr Anaesth. 2011;21(3):222–37.CrossRefPubMed

32.

Patel P, Mulla H, Tanna S, Pandya H. Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch Dis Child. 2010;95(6):484–7.CrossRefPubMed

33.

Wiles JR, Isemann B, Mizuno T, Tabangin ME, Ward LP, Akinbi H, et al. Pharmacokinetics of oral methadone in the treatment of neonatal abstinence syndrome: a pilot study. J Pediatr. 2015;167(6):1214–1220 e3.CrossRefPubMedPubMedCentral

34.

Patel P, Mulla H, Kairamkonda V, Spooner N, Gade S, Della Pasqua O, et al. Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. Br J Clin Pharmacol. 2013;75(3):805–13.CrossRefPubMedPubMedCentral

35.

Giaccone A, Zuppa AF, Sood B, Cohen MS, O’Byrne ML, Moorthy G, et al. Milrinone Pharmacokinetics and pharmacodynamics in neonates with persistent pulmonary hypertension of the newborn. Am J Perinatol. 2017;34(8):749–58.CrossRefPubMedPubMedCentral

36.

Hallik M, Tasa T, Starkopf J, Metsvaht T. Dosing of milrinone in preterm neonates to prevent postligation cardiac syndrome: simulation study suggests need for bolus infusion. Neonatology. 2017;111(1):8–11.CrossRefPubMed

37.

Chihoho B, Sage AB, Smolenski RT, Vazir A, Rose ML, Banner NR, et al. A clinical assay for the measurement of milrinone in plasma by HPLC mass spectrometry. Biomed Chromatogr. 2012;26(5):566–70.CrossRefPubMed

38.

Gavra P, Nguyen AQ, Theoret Y, Litalien C, Denault AY, Varin F. A specific and sensitive HPLC–MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. Ther Drug Monit. 2014;36(5):663–8.CrossRefPubMed

39.

Emoto C, Fukuda T, Mizuno T, Schniedewind B, Christians U, Adams DM, et al. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants. CPT Pharmacomet Syst Pharmacol. 2016;5(8):411–7.CrossRef

40.

Children’s Hospital Medical Center, Cincinnati. Milrinone pharmacokinetics and acute kidney injury (MIL-PK) [ClinicalTrials.gov identifier NCT01966237]. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 7 Dec 2018.

Titel: Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery
verfasst von: Tomoyuki Mizuno
Katja M. Gist
Zhiqian Gao
Michael F. Wempe
Jeffrey Alten
David S. Cooper
Stuart L. Goldstein
Alexander A. Vinks
Publikationsdatum: 03.01.2019
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 6/2019
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-018-0729-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery

Abstract

Background and Objective

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background and Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone

Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin